The time courses of changes in cyclic nucleotide levels in monocytes have been studied. Histamine and prostaglandin E2 (PGE2) produced a rapid rise in cyclic AMP (peak 15min) levels, which returned to normal within 4h, whereas cholera toxin, NaF and phosphodiesterase inhibitors produced slow sustained rises lasting over 24 h. With the exception of isobutylmethylxanthine (1O Mmolh1), none of these reagents altered cyclic GMP levels. oa -Adrenergic and nicotinic cholinergic receptor-ligand interactions and imidazole produced rapid and relatively short-lived falls in cyclic AMP, and rises in cyclic GMP. In contrast, prostaglandin synthetase inhibitors produced delayed but more sustained falls in cyclic AMP but no rises in cyclic GMP. Agents that increased cyclic AMP decreased complement-component-C2 production, and those that decreased cyclic AMP increased C2 production. Agents that increased cyclic GMP alone (ascorbate, nitroprusside and prostaglandin F2a) did not affect C2 production. Antigen-antibody complexes that stimulate C2 synthesis produced falls in cyclic AMP and rises in cyclic GMP similar to those produced by adrenergic and cholinergic ligands. Serum-treated complexes and anaphylatoxins, which inhibited C2 production, were associated with changes in cyclic AMP similar to those produced by histamine and PGE2. These data suggest that there are two transmembrane signals involved in the regulation of C2 production by monocytes. The inhibitory signal is adenylyl cyclase activation. The stimulatory signal is not so obvious, but may be Ca2 + influx, since the time courses of changes in cyclic nucleotides produced by agents that stimulate C2 synthesis are identical, and a, -adrenergic agonists cause the formation of Ca2 + channels.
The complement system consists of a series of plasma proteins that plays a major role in host defence. Although hepatocytes are thought to synthesize over 90% of the C3, C6 and factor B that are Abbreviations used: the nomenclature of complement components is that recommended by the World Health Organisation (1968) present in the plasma (Alper et al., 1968; Alper & Rosen, 1976; Hobart et al., 1977) , local production of complement components occurs at sites of inflammation (Ruddy & Colten, 1974) . Metabolic studies have shown that approximately half of the C3 present in the synovial fluid from inflamed joints is synthesized locally (Ruddy & Colten, 1974) . The mononuclear phagocyte, which has been shown to synthesize a number of functionally active complement components, including C2, B, P, D and C3 (Einstein et al., 1976; Whaley, 1980; Strunk et al., 1983) , is the cell most likely to be responsible for this local synthesis. The observations that macrophages isolated from chronically inflamed synovial joints synthesize greater quantities of complement components than do cells
Vol. 222 from non-inflamed joints, or monocyte-derived macrophages (De Ceulaer et al., 1980) , supports this notion. The factors that control the synthesis of complement components by mononuclear phagocytes are only beginning to be defined. We have been investigating the effect of inflammatory mediators and defined pharmacological agents on complement synthesis, and have shown that agents such as histamine and PGE2 , which activate adenylyl cyclase, inhibit the synthesis of complement components, whereas imidazole, which decreases cyclic AMP, increases their synthesis ). These observations suggested that changes in the intracellular concentrations of cyclic AMP may control the synthesis of complement components by mononuclear phagocytes. In other experiments in which we have investigated the effects of antigen-antibody complexes on complement synthesis, we have shown that antigenantibody complexes (IC) that bind to Fc receptors have a stimulatory effect (McPhaden et al., 1981) , whereas serum-treated IC (SIC), which act on the C3b receptor (CR1), are inhibitory (Whaley et al., 1983a) . The anaphylatoxins C3a, C5a and their desarginyl derivatives, also inhibit the synthesis of the second component of complement (C2) .
Here we present the results of experiments showing the kinetics of the changes of cyclic AMP and cyclic GMP levels in cultured human monocytes after exposure to defined pharmacological agents, IC, SIC and anaphylatoxins. We also show that the changes in cyclic AMP levels correlate inversely with changes in the concentrations of C2 in the monocyte culture medium. Complement components, antisera and antigen-antibody complexes C3b was prepared from purified C3 (Tack & Prahl, 1976 ) by using a solid-phase cobra-venomfactor-dependent C3 convertase (Gitlin et al., 1975) . C3b was polymerized by using DTSP (Pierce and Warriner, Chester, Cheshire, U.K.) as described previously (Hamilton et al., 1983) . Analysis of DTSP-polymerized C3b by SDS/polyacrylamide-gel electrophoresis run under nonreducing conditions revealed that 50% of the C3b was polymerized, and oligomers, ranging from dimer to hexamer and larger, were formed. Human CR1 (Fearon, 1980) and the porcine anaphylatoxins C3a and C5a and their desarginyl derivatives (Damerau et al., 1980) were prepared by published techniques. Antisera to C3 and CR1 were prepared by the immunization of rabbits with the antigens emulsified in Freund's complete adjuvant followed 1 month later by three booster injections spaced at 2-week intervals with the antigens emulsified in Freund's incomplete adjuvant. The rabbits were bled 10 days after the final injection. Fab fragments of the IgG fractions of the antisera were prepared by papain digestion (Porter, 1959) . IC were prepared at equivalence by using sterile bovine serum albumin and sterile I25I-labelled immunoadsorbent-purified rabbit anti-(bovine serum albumin). IC were added to cultures within 5min of their formation. SIC were prepared by solubilizing I 25I-labelled immune precipitates formed at equivalence with the normal human serum. SIC were separated from other complement components by gel-filtration chromatography using Sepharose 6B, and then sterilized by Millipore filtration (Whaley et al., 1983a Initially the time points for these kinetic studies were 0, 5, 15 and 45 s, 2, 5, 15 and 30min. However, it became obvious that, for all the reagents under investigation, peaks or troughs in cyclic nucleotide levels did not occur at intervals of less than 1 min. We therefore decided to sample at 0, 2, 5, 15, 30 and 60min, 2, 4, 8 and 24h. At each point a control culture to which no reagent had been added was harvested in the same way. Replicate cultures were exposed to the reagent under study, or no reagent, and 24h later the supernatant was removed for measurement of C2 content by a stoichiometric haemolytic assay (Rapp & Borsos, 1971 ). The monolayer was washed and lysed in 2% (w/v) SDS and the DNA content measured by spectrofluorimetry (Einstein et al., 1976) . The DNA content of the monolayers used in the present study was between 2 and 4pg (i.e. between 3 x 105 and 6 x 105 monocytes/culture). Dose-response curves were constructed once the time of the maximal change in cyclic nucleotide levels had been defined on the basis of kinetic assays. In these experiments, different concentrations of reagent were added to the cultures, and incubation continued until maximal change in cyclic nucleotide levels had occurred. Replicate cultures were incubated for 24h in order to measure the C2 content of the supernatants and the DNA content of the monolayers.
Cyclic nucleotide assays
The freeze-dried material from the ethanol extracts of the monolayers were dissolved in 500 pl of acetate buffer (SOmmol -11), pH4.75, acetylated with acetic anhydride (130mmol-1-1) and then assayed for their cyclic AMP and cyclic GMP content by using a modification of the method of Harper & Brooker (1975 In addition to background and 100%-binding controls, in some assays specificity controls were included. These consisted of unlabelled cyclic AMP, cyclic GMP or extracts that had been pretreated with cyclic nucleotide phosphodiesterase (Sigma). After digestion, the phosphodiesterase was inactivated by heating for 2min at 90°C.
Di'gestion with phosphodiesterase always decreased cyclic nucleotide concentrations to zero.
All assays were performed in duplicate; when results of replicate assays differed by more than 10%, the assay was repeated. By using these assays we were able to measure confidently 5 fmol of cyclic AMP and 2.5fmol of cyclic GMP.
In order to exclude the possibility that agents which inhibited C2 production were cytotoxic or were inhibiting monocyte protein synthesis nonspecifically, the following experiments were performed. Monocytes were cultured for 5 days as described above. After replacing the culture supernatant with fresh medium on day 5, the agent under study was added. In one series of experiments the ability of monocytes to exclude Trypan Blue was measured after 24h . In a second series, the supernatant was removed after 24h, and the washed monolayer was lysed in 1.5 ml of Triton X-100 (0.05%). The supernatants and lysates were assayed for LDH content by a standard technique (Strunk et al., 1980) . LDH release was expressed as a percentage of the total (intracellular + extracellular). The lysozyme content of the supernatants was assayed by measuring the lysis of Micrococcus lysodeikticus (Sigma) by the method of Strunk et al. (1980) . The results were expressed as units/gg of DNA. One unit of activity is that which will produce a £A450 of 0.001/min at pH 6.4 and 25°C with a suspension of Micrococcus lysodeikticus (0.2mg/ml) as substrate in a 2.6ml reaction volume and a light-path of 1 cm.
Results

Cyclic nucleotide levels in cultured monocytes
The mean levels of cyclic AMP and cyclic GMP in control monocytes (31 cultures) that had been cultured for 5 days were 277. Studies of the time courses of elevations of cyclic AMP induced by pharmacological agents
In order to define the kinetics of changes in cyclic AMP levels in monocytes, we studied the actions of agents that (a) activate adenylyl cyclase by specific cell membrane receptors (histamine, PGE2), (b) act on the regulatory unit of the holoenzyme (cholera toxin and NaF) and (c) inhibit phosphodiesterase activity (theophylline and IBMX). Histamine (1 gmol * 1-') and PGE2
(10pmol [ 1-1) produced a rapid rise in cyclic AMP that reached a peak at 15 min, and returned to control values by 8h (Fig. 1) . NaF (I00nmol 1-I) and cholera toxin (lOng/ml) produced a slower increase in cyclic AMP that reached a peak at 2h and remained elevated at 24h (Fig. 1) . Theophylline (I00imol 1-l) and IBMX (l0pmol 1-1) also produced slower but sustained elevations in cyclic AMP and, as with agents acting on the regulatory unit of adenylyl cyclase, the peak level was achieved by 2h, and at 24h, cyclic AMP levels were still above control values (Fig. 1 degradation of newly synthesized C2 was excluded by showing that functionally purified C2 (Ruddy & Austen, 1967) was not degraded more rapidly in cultures exposed to the reagents under study. Thus decreased concentrations of C2 in the culture supernatants are due to reduced production.
PGF2a ( Oyrmoli-1) did not affect C2 production or cyclic AMP levels.
Studies ofthe time courses ofdecreases in cyclic AMP induced by pharmacological agents The a-adrenergic agonist phenylephrine (1 pmol * 1-1) produced an immediate fall in intracellular cyclic AMP that reached the lowest level 30min after the addition of the agent to the culture and returned to normal after 8 h (Fig. 2) . The f3-adrenergic agonist isoprenaline (100 imol *-1-1) had no effect on cyclic AMP levels. The cholinergic agonist carbamylcholine (1 !Lmol -1-) and imidazole (10 p mol -1-I) also produced marked lowering of cyclic AMP levels, the lowest level occurring after 30 min and returning to control values by 8 h. Indomethacin (1 pmol 1-1) and ETYA
(1 umol * 1-1) also decreased cyclic AMP levels (Fig. 2) . However, unlike the a-adrenergic and cholinergic ligands, the fall, which did not begin until after 15 min of exposure, was gradual, with the lowest levels occurring after 60 min and persisting throughout 24h. The mean control level of cyclic AMP for the sets of cultures treated with phenylephrine, indomethacin and ETYA and imidazole was 328 (±3) fmol/pg of DNA. The minimum levels for the reagents used were as fol- ligand was 293 (± 2.3). C2 levels were significantly elevated in cultures exposed to phenylephrine, carbamylcholine, imidazole, indomethacin and ETYA (Fig. 2) . Effect of agents on cyclic GMP levels Histamine, PGE2, cholera toxin, NaF, theophylline, indomethacin and ETYA did not affect cyclic GMP levels. At high concentrations (10 tmol *1-1) IBMX produced a small elevation in cyclic GMP, which did not achieve statistical significance. Sodium nitroprusside (10 jumol l-1) and sodium ascorbate (1OMmol.1-1) produced marked elevations in cyclic GMP, the peak level being reached after 60min and beginning to fall by 8h (Fig. 3) . The rise in cyclic GMP after the addition of PGF2a to the cultures was less pronounced, reaching a peak by 30 min and lasting less than 4 h. The mean control cyclic GMP level in cultures treated with nitroprusside and PGF2c was 14.3 fmol/ug of DNA (± 0.3). The peak levels obtained with sodium nitroprusside and PGF2a were 31.9 (±0.5) and 19.7 (±0.8) fmol/Mg respectively.
The mean control level of cyclic GMP in cultures treated with sodium ascorbate were 19.6 (± 1.4) fmol/ug of DNA. The peak value produced by this agent was 50.7 (±6.2) fmol/pg. C2 levels in cultures exposed to sodium nitroprusside, sodium ascorbate and PGF2a did not differ from those in control cultures.
Phenylephrine (1 ymol l-1), carbamylcholine
(1 yimol * 1-1) and imidazole (I 10 mol * 1-1) caused increases in cyclic GMP; the time courses and the size of the increases were similar to those produced by PGF2a. The level of cyclic GMP in the control cultures for phenylephrine and imidazole were 23.5 fmol/pjg of DNA (± 1. 1) and the peak levels for these agents were 33.7 (+ 1.1) and 33.0 (±0.2) fmol/pg respectively. The mean control level in carbamylcholine-treated cultures was 22.5 (± 1.7) fmol/pg of DNA and the peak level achieved with this agent was 45.2 (±2.1) fmol/,ug.
Reversibility of effects of histamine and cholinergic and adrenergic ligands
Histamine (1 umol 1-I) was added to a series of monocyte cultures in the presence and absence of cimetidine (0.01-10Imol *l-1), chlorpheniramine (0.01-IOmoll-1) or indomethacin (O1umoll1 1). Cyclic AMP levels were measured after 15min
and C2 levels after 24h. Cimetidine (1 pmol lh 1)
completely inhibited the elevation in cyclic AMP and the fall in C2 production produced by histamine, whereas chlorpheniramine and indomethacin had no effect on these actions. Neither cimetidine nor chlorpheniramine alone had any effect on cyclic nucleotide levels or C2 synthesis (results not shown). Carbamylcholine (l 4umol l-1) was added to a series of cultures in the presence or absence of D-tubocurarine (10 000-1 nmol *l-1) or atropine (10000-1 nmol 1-1 ). Cyclic AMP and cyclic GMP levels were measured after 30 min and C2 levels in the supernatants of replicate cultures after 24h. DTubocurarine (1Onmol *l-1) abrogated completely the effects of carbamylcholine, whereas atropine was ineffective (results not shown). The changes in cyclic nucleotide levels and C2 synthesis produced by phenylephrine (1 pmol * 1-1) were inhibited by prazosin (10nmol.1') and phentolamine
(1 kLmol * 1-1), whereas yohimbine and propranolol (both at 10-0.1 mol * 1-1) had no effect. None of these antagonists affected cyclic AMP levels or C2 production when added to cultures in the absence of any agonists (results not shown). Effects of antigen-antibody complexes on cyclic AMP, cyclic GMP and C2 production IC and DTSP-polymerized IgG, IgG, and IgG3 produced falls in cyclic AMP levels and increased synthesis of C2 (Fig. 4) . The fall in cyclic AMP began within the first few minutes of the addition of these reagents to the culture, and minimum levels were achieved within 30min. After 4h cyclic AMP levels returned to control values. This pattern of change is similar to that found for phenylephrine, carbamylcholine and imidazole (Fig. 2) IgG4 had no effect on cyclic GMP levels. SIC (300ng of IgG/ml) and polymerized C3b (1Opg/ml) produced a rapid rise in cyclic AMP that reached a peak at 15min and returned to normal by 4h (Fig. 4) . This pattern is similar to that produced by histamine and PGE2 (Fig. 1) . Levels of C2 were reduced in cultures treated with SIC and polymerized C3b. By using the criteria described above, the decreased C2 content in these cultures was due to reduced production. The mean control cyclic AMP level for this set of cultures was 404 (±17) fmol/ug of DNA. The mean peak level of cyclic AMP in cultures exposed to SIC was 802 (±0.5) fmol/ug, whereas after exposure to polymerized C3b it was 817 (±26) fmol/pg.
Reversal ofeffects ofSIC andpolymerized C3b on C2 production The elevations in cyclic AMP produced by SIC (37.5-300ng/ml) and polymerized C3b (0.01-lOpg/ml) were abrogated by the concomitant administration of Fab fragments (1O0g/ml) of anti-CR1 or anti-C3, but not by normal rabbit Fab fragments (Fig. 5) . Fab fragments of anti-C3 and anti-CR1 also prevented the reduction in C2 production in cultures exposed to SIC or polymerized C3b. Indomethacin (10jimol 1-1) did not affect the changes in cyclic AMP or C2 production produced by SIC or polymerized C3b. Effect of anaphylatoxins on cyclic AMP and C2 production C3a, C5a and des-Arg-C5a (all at l jsmol -11) produced changes in cyclic AMP levels. After an initial rapid rise that reached a peak after 15 min, the levels returned to control values by 4h (results not shown). The control cyclic AMP level in this series of cultures was 174fmol/jg of DNA (mean for two cultures), and the peak levels for C3a, C5a and des-Arg-C5a were 518, 643 and 702 fmol/pg respectively. C2 levels were reduced in anaphylatoxin-treated cultures, the decrease being due to reduced production. Anaphylatoxins did not change levels of cyclic GMP. Relationship between changes in cyclic AMP and C2 production Does-response studies were performed on histamine, PGE2, NaF, theophylline, IBMX, ETYA, Vol. 222 indomethacin and imidazole. Cyclic AMP levels were measured after 15min for histamine and PGE2, 1 h for NaF, theophylline and IBMX, 30min for imidazole and 60min for ETYA and indomethacin, which were the times required to achieve maximal changes. C2 levels were measured after 24h incubation in the presence of the reagent. When the cyclic AMP levels were plotted against the C2 concentrations there was an inverse correlation between C2 levels and log (peak cyclic AMP level). The correlation coefficient for those agents that increased cyclic AMP was -0.98, and was -0.97 for those that decreased cyclic AMP (results not shown). Lysozyme synthesis and LDH release Agents that inhibited C2 production did not reduce lysozyme secretion or increase LDH release (Table 1) .
Discussion
Cyclic AMP provides a link between membrane signals and the expression of many cellular functions, and is therefore regarded as a second signal. Many mononuclear-phagocytic functions have been shown to be modulated by changes in intracellular cyclic AMP levels, including migration (Pick, 1972) , response to MIF (migration-inhibitory factor) (Koopman et al., 1973) interferoninduced tumoricidal activity (Schultz et al., 1979) plasminogen activator (Vassalli et al., 1976) and lysozomal enzyme secretion (Weissmann et al., 1971) , lipopolysaccharide-induced collagenase synthesis (McCarthy et al., 1980) and Fc-receptormediated phagocytosis (Muschel et al., 1977) . Since pharmacological agents that increase cyclic AMP (histamine, prostaglandins and phosphodiesterase inhibitors) decrease the synthesis of C2 and other complement components by human monocytes , it appears that cyclic AMP is important in the regulation of this cellular function.
In order to confirm this conclusion, and to demonstrate whether the changes in the levels of cyclic AMP were closely related to changes in C2 synthesis, we undertook to measure levels of cyclic nucleotides in monocytes by radioimmunoassay. The levels of cyclic AMP and cyclic GMP measured in control cultures on day 5 are similar to those reported previously by other workers (Gallin et al., 1978; Herlin & Kragballe, 1981) . We waited until day 5 to study cyclic nucleotide levels because on day 0, immediately after plating out, there is a pronounced rise in monocyte cyclic AMP levels, which do not return to baseline values until 24h.
This rise masks changes seen with agents that increase cyclic AMP.
The time courses of the increases in cyclic AMP were dependent on the site of action of the pharmacological agent under investigation. Adenylyl cyclase activators, acting via hormone receptors, produced an early rise in cyclic AMP that reached a peak after 15 min and returned to baseline levels by 4h (Fig. 1) . Agents that acted on the regulatory unit of adenylyl cyclase, or inhibited phosphodiesterase activity, produced much slower, but more sustained, elevations. The abrogation of the histamine effect by cimetidine rather than chlorpheniramine supports the idea that the elevation of cyclic AMP produced by histamine is mediated by adenylyl cyclase activation, as H2 receptors are known to activate adenylyl cyclase (Bourne et al., 1971) .
Two time-course patterns of decrease in cyclic AMP levels were produced. The first pattern, produced by the a-adrenergic agonist phenylephrine and the cholinergic ligand carbamylcholine, showed an early fall without any delay (Fig. 2) . The second pattern of reduction, that produced by inhibitors of PG synthesis, occurred later and was more sustained. This difference in time course, together with the failure of prostaglandin synthetase inhibitors to increase levels of cyclic GMP, indicates that the mode of action is distinct from the former agents. The decrease in cyclic AMP, elevation of cyclic GMP and increased C2 production by phenylephrine was reversed by prazosin, but not by yohimbine, showing that these effects were mediated by al -adrenergic receptors. The observation that the actions of carbamylcholine on cyclic AMP, cyclic GMP and C2 production were reversed by D-tubocurarine rather than atropine, confirms that this ligand is acting on nicotinic receptors. As stimulation of alc-adrenergic receptors leads to the formation of calcium channels (Takai et al., 1981) , the first pattern of cyclic AMP decrease could be due to activation of phosphodiesterase (Cheung, 1971) or to the modulation of adenylyl cyclase activity secondary to the intracellular influx of calcium. The fall in cyclic AMP produced by inhibitors of prostaglandin synthesis, could be explained on the assumption that endogenous production of prostaglandin regulates monocyte cyclic AMP levels. If so, then the time taken for the fall to occur could represent the combined time taken for the inhibitor to decrease prostaglandin production, and for the effect of the decrease to affect adenylyl cyclase activity.
The patterns of changes in cyclic AMP levels induced by polymerized C3b and serum-treated complexes were the same as those produced by histamine and PGE2 (Fig. 4) . The observation that the effects of these agents on cyclic AMP and C2 production were abrogated by Fab fragments of anti-C3 and anti-CR1 show that the effects are mediated by a C3 cleavage fragment bound to the complexes binding with CR1. Furthermore, they suggest that CRI-receptor-ligand interactions activate adenylyl cyclase. Recently, it has been shown that C3b stimulates prostaglandin synthesis by monocytes (Rutherford & Shenkin, 1983) . The failure of indomethacin to abrogate the effects of SIC and polymerized C3b shows that prostaglandin formation is not the cause of the adenylyl cyclase activation or the reduction in C2 production after the addition of these agents to monocyte cultures. Anaphylatoxins, which inhibit C2 production, also increased cyclic AMP, the pattern of change suggesting that C3a and C5a receptors are linked to adenylyl cyclase-like histamine and PGE2. Stimulation of prostaglandin production by anaphylatoxins does not account for the changes in cyclic AMP or C2 production, as shown by the failure of indomethacin to inhibit these effects.
The decreases in cyclic AMP produced by IC and polymerized IgG1 and IgG3 (Fig. 4) (Curtain et al., 1981) .
The changes in monocyte cyclic AMP levels were always associated with changes in C2 production (Figs. 1, 2 and 4 ). The dose-response studies, which showed that cyclic AMP and C2 levels were inversely correlated, supports the idea that changes in cyclic AMP levels play an important role in the modulation of C2 production.
The results of Trypan Blue-exclusion tests and LDH-release assays show that agents which inhibit C2 production are not cytotoxic. Furthermore, as they do not inhibit lysozyme secretion, their inhibitory action is selective. Lysozyme secretion is unaffected by the state ofmacrophage activation, and is therefore considered to be constitutive (Gordon, 1980) . In contrast, secretion of neutral proteinases such as plasminogen activator is induced by stimuli that cause macrophage activation. As synthesis of C2 is increased during macrophage activation (Littman & Ruddy, 1977; McPhaden et al., 1982) , it can be considered to be an induced secretory product. Like C2 synthesis, that of plasminogen activator is inhibited by increasing cyclic AMP, whereas lysozyme secretion continues unabated (Rosen et al., 1978) .
The results of these studies suggest that the transmembrane signal responsible for the decrease in C2 production is adenylyl cyclase activation. It is possible that the signal for stimulation of C2 synthesis is calcium-channel formation. If so, it remains to be determined whether the calcium influx stimulates C2 production by activating a calcium-dependent protein kinase, or whether the reduced levels of cyclic AMP play a role by inhibiting cyclic AMP-dependent protein kinase. Finally, our data suggest that cyclic GMP does not play a significant role in the modulation of C2 production by monocytes.
